January 2025: The defendants in the MDL have filed a new motion to dismiss many of the claims made in the plaintiffs master complaint
Cuomo A, Bolognesi S, Goracci A, Ciuoli C, Crescenzi BB, Maina G, et al
BMJ Open 13 , e068652 (2023)
The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration
On top of keeping you fuller for longer, this means that the sugar from your meal will be released into your bloodstream more slowly that means more sustained energy levels and more stable blood sugar